Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tolmetin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 2/20 | 1.00 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 1.00 |
| ▸ | CXCL8 | P10145 | 1/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 1/20 | 1.00 |
| ▸ | GLO1 | Q04760 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 2/20 | 0.37 |
| ▸ | CES1 | P23141 | 2/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolmetin SCHEMBL11325188 | 1.00 | PTGS2 (1.00) | PTGS2CXCL8AKR1B1PTGS1GLO1 | |
| Tolmetin SCHEMBL5980424 | 0.98 | PTGS2 (0.97) | PTGS2CXCL8AKR1B1PTGS1GLO1 | |
| Tolmetin SCHEMBL28562007 | 0.98 | PTGS2 (0.97) | PTGS2CXCL8AKR1B1PTGS1GLO1 | |
| Tolmetin SCHEMBL29461 | 0.98 | PTGS2 (0.97) | PTGS2CXCL8AKR1B1PTGS1GLO1 | |
| Tolmetin SCHEMBL11486460 | 0.98 | PTGS2 (0.97) | PTGS2CXCL8AKR1B1PTGS1GLO1 | |
| Tolmetin SCHEMBL3500471 | 0.97 | PTGS2 (0.94) | PTGS2CXCL8AKR1B1PTGS1GLO1 | |
| Tolmetin SCHEMBL28723181 | 0.97 | PTGS2 (0.94) | PTGS2CXCL8AKR1B1PTGS1GLO1 | |
| SCHEMBL8729441 | 0.96 | PTGS2 (0.91) | PTGS2CXCL8AKR1B1PTGS1GLO1 | |
| Tolmetin SCHEMBL10814156 | 0.94 | PTGS2 (0.89) | PTGS2CXCL8AKR1B1PTGS1GLO1 | |
| Tolmetin SCHEMBL28221483 | 0.93 | PTGS2 (0.86) | PTGS2CXCL8AKR1B1PTGS1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 64257 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747263-A1 | LIPID NANOPARTICLES AND USES THEREOF | University of Connecticut (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| US-20260130928-A1 | COMBINATION OF AKR1C3 ACTIVATED ANTICANCER PRODRUG COMPOUND AND ANALGESIC DRUG FOR TREATING CANCER PATIENTS ACCOMPANIED BY PAIN | ASCENTAWITS PHARMACEUTICALS LTD (CN) | 2026-05-14 | — | — | US | claimed |
| EP-4739297-A1 | MODULATORS OF LYPOXYGENASES FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2026-05-13 | — | — | EP | claimed |
| CN-122028914-A | Combination therapy for autoimmune disorders | 拜奥海芬治疗学有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260115209-A1 | COMBINATION THERAPY INCLUDING COX-2 INHIBITOR FOR THE TREATMENT OF CANCER | UNIV CALIFORNIA (US) | 2026-04-30 | — | — | US | claimed |
| US-12605432-B2 | Combinations for antigen based therapy | DIAMYD MEDICAL AB (SE) | 2026-04-21 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-12600696-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2026-04-14 | — | — | US | claimed |
| EP-0055870-A1 | Pyridylmethyl esters of selected bio-affecting carboxylic acids, process for preparing and pharmaceutical composition comprising the same | MERCK & CO. INC. (US) | 1982-07-14 | — | — | EP | claimed |
| EP-0040899-A2 | Method of delivering drug with aid of effervescent activity generated in environment of use | ALZA CORPORATION (US) | 1981-12-02 | — | — | EP | claimed |
| EP-0039051-A2 | Mannich-base hydroxamic acid prodrugs for the improved bioavailability of non-steroidal anti-inflammatory agents, a process for preparing and a pharmaceutical composition containing them | MERCK & CO. INC. (US) | 1981-11-04 | — | — | EP | claimed |
| EP-0038698-A2 | Pharmaceutical compositions | Smith and Nephew Associated Companies p.l.c. (GB) | 1981-10-28 | — | — | EP | claimed |
| US-4282216-A | Topical anti-inflammatory drug therapy | JOHNSON & JOHNSON (US) | 1981-08-04 | — | — | US | claimed |
| US-4246176-A | Synthesis of 5-aroyl-1-hydrocarbylpyrrole-2-acetic acid | ETHYL CORPORATION (US) | 1981-01-20 | — | — | US | claimed |
| EP-0017169-A1 | Improved anti-inflammatory combinations having reduced ulcerogenicity | MERCK & CO. INC. (US) | 1980-10-15 | — | — | EP | claimed |
| WO-1980000661-A1 | PHARMACEUTICAL PREPARATIONS | CROFT J (NZ) | 1980-04-17 | — | — | WO | claimed |
| EP-0010061-A1 | Pharmaceutical preparations containing a mollusc extract | Mc Farlane, Stuart John (NZ) | 1980-04-16 | — | — | EP | claimed |
| US-4132788-A | 5-AROYL-1-LOWERALKYL-PYRROLE-2-ACETIC ACID DERIVATIVES, ASPIRIN OR ACETAMINOPHEN | MCNEIL LABORATORIES, INC. (US) | 1979-01-02 | — | — | US | claimed |